Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis

Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.To validate graded kidney respon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Muchtar, Eli (VerfasserIn) , Wisniowski, Brendan (VerfasserIn) , Geyer, Susan (VerfasserIn) , Palladini, Giovanni (VerfasserIn) , Milani, Paolo (VerfasserIn) , Merlini, Giampaolo (VerfasserIn) , Schönland, Stefan (VerfasserIn) , Veelken, Kaya (VerfasserIn) , Hegenbart, Ute (VerfasserIn) , Leung, Nelson (VerfasserIn) , Dispenzieri, Angela (VerfasserIn) , Kumar, Shaji K. (VerfasserIn) , Kastritis, Efstathios (VerfasserIn) , Dimopoulos, Meletios A. (VerfasserIn) , Liedtke, Michaela (VerfasserIn) , Ulloa, Patricia (VerfasserIn) , Sanchorawala, Vaishali (VerfasserIn) , Szalat, Raphael (VerfasserIn) , Dooley, Katharine (VerfasserIn) , Landau, Heather (VerfasserIn) , Petrlik, Erica (VerfasserIn) , Lentzsch, Suzanne (VerfasserIn) , Coltoff, Alexander (VerfasserIn) , Bladé, Joan (VerfasserIn) , Cibeira, M. Teresa (VerfasserIn) , Cohen, Oliver (VerfasserIn) , Foard, Darren (VerfasserIn) , Gillmore, Jullian (VerfasserIn) , Lachmann, Helen (VerfasserIn) , Wechalekar, Ashutosh (VerfasserIn) , Gertz, Morie A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: October 2024
In: JAMA oncology
Year: 2024, Jahrgang: 10, Heft: 10, Pages: 1362-1369
ISSN:2374-2445
DOI:10.1001/jamaoncol.2024.2629
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1001/jamaoncol.2024.2629
Volltext
Verfasserangaben:Eli Muchtar, Brendan Wisniowski, Susan Geyer, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Nelson Leung, Angela Dispenzieri, Shaji K. Kumar, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Patricia Ulloa, Vaishali Sanchorawala, Raphael Szalat, Katharine Dooley, Heather Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff, Joan Bladé, M. Teresa Cibeira, Oliver Cohen, Darren Foard, Jullian Gillmore, Helen Lachmann, Ashutosh Wechalekar, Morie A. Gertz

MARC

LEADER 00000naa a2200000 c 4500
001 1938275470
003 DE-627
005 20251013102920.0
007 cr uuu---uuuuu
008 251013s2024 xx |||||o 00| ||eng c
024 7 |a 10.1001/jamaoncol.2024.2629  |2 doi 
035 |a (DE-627)1938275470 
035 |a (DE-599)KXP1938275470 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Muchtar, Eli  |e VerfasserIn  |0 (DE-588)1311261044  |0 (DE-627)1871263093  |4 aut 
245 1 0 |a Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis  |c Eli Muchtar, Brendan Wisniowski, Susan Geyer, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Nelson Leung, Angela Dispenzieri, Shaji K. Kumar, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Patricia Ulloa, Vaishali Sanchorawala, Raphael Szalat, Katharine Dooley, Heather Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff, Joan Bladé, M. Teresa Cibeira, Oliver Cohen, Darren Foard, Jullian Gillmore, Helen Lachmann, Ashutosh Wechalekar, Morie A. Gertz 
264 1 |c October 2024 
300 |b Illustrationen 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 1. August 2024 
500 |a Gesehen am 13.10.2025 
520 |a Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.To validate graded kidney response criteria and their association with kidney and overall survival (OS).This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.Cumulative incidence of progression to KRT and OS.Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival. 
700 1 |a Wisniowski, Brendan  |e VerfasserIn  |4 aut 
700 1 |a Geyer, Susan  |e VerfasserIn  |4 aut 
700 1 |a Palladini, Giovanni  |e VerfasserIn  |4 aut 
700 1 |a Milani, Paolo  |e VerfasserIn  |4 aut 
700 1 |a Merlini, Giampaolo  |e VerfasserIn  |4 aut 
700 1 |a Schönland, Stefan  |d 1969-  |e VerfasserIn  |0 (DE-588)122405226  |0 (DE-627)705896137  |0 (DE-576)293255792  |4 aut 
700 1 |a Veelken, Kaya  |d 1988-  |e VerfasserIn  |0 (DE-588)1155327845  |0 (DE-627)1016744269  |0 (DE-576)501617655  |4 aut 
700 1 |a Hegenbart, Ute  |e VerfasserIn  |0 (DE-588)1028373708  |0 (DE-627)73062157X  |0 (DE-576)35901903X  |4 aut 
700 1 |a Leung, Nelson  |e VerfasserIn  |4 aut 
700 1 |a Dispenzieri, Angela  |e VerfasserIn  |4 aut 
700 1 |a Kumar, Shaji K.  |e VerfasserIn  |4 aut 
700 1 |a Kastritis, Efstathios  |e VerfasserIn  |4 aut 
700 1 |a Dimopoulos, Meletios A.  |e VerfasserIn  |4 aut 
700 1 |a Liedtke, Michaela  |e VerfasserIn  |4 aut 
700 1 |a Ulloa, Patricia  |e VerfasserIn  |4 aut 
700 1 |a Sanchorawala, Vaishali  |e VerfasserIn  |4 aut 
700 1 |a Szalat, Raphael  |e VerfasserIn  |4 aut 
700 1 |a Dooley, Katharine  |e VerfasserIn  |4 aut 
700 1 |a Landau, Heather  |e VerfasserIn  |4 aut 
700 1 |a Petrlik, Erica  |e VerfasserIn  |4 aut 
700 1 |a Lentzsch, Suzanne  |e VerfasserIn  |4 aut 
700 1 |a Coltoff, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Bladé, Joan  |e VerfasserIn  |4 aut 
700 1 |a Cibeira, M. Teresa  |e VerfasserIn  |4 aut 
700 1 |a Cohen, Oliver  |e VerfasserIn  |4 aut 
700 1 |a Foard, Darren  |e VerfasserIn  |4 aut 
700 1 |a Gillmore, Jullian  |e VerfasserIn  |4 aut 
700 1 |a Lachmann, Helen  |e VerfasserIn  |4 aut 
700 1 |a Wechalekar, Ashutosh  |e VerfasserIn  |4 aut 
700 1 |a Gertz, Morie A.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t JAMA oncology  |d Chicago, Ill. : American Medical Association, 2015  |g 10(2024), 10 vom: Okt., Seite 1362-1369  |h Online-Ressource  |w (DE-627)818494301  |w (DE-600)2810928-4  |w (DE-576)426501284  |x 2374-2445  |7 nnas  |a Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis 
773 1 8 |g volume:10  |g year:2024  |g number:10  |g month:10  |g pages:1362-1369  |g extent:8  |a Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis 
856 4 0 |u https://doi.org/10.1001/jamaoncol.2024.2629  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20251013 
993 |a Article 
994 |a 2024 
998 |g 1028373708  |a Hegenbart, Ute  |m 1028373708:Hegenbart, Ute  |d 910000  |d 910100  |d 50000  |e 910000PH1028373708  |e 910100PH1028373708  |e 50000PH1028373708  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 8 
998 |g 1155327845  |a Veelken, Kaya  |m 1155327845:Veelken, Kaya  |d 910000  |d 910100  |e 910000PV1155327845  |e 910100PV1155327845  |k 0/910000/  |k 1/910000/910100/  |p 7 
998 |g 122405226  |a Schönland, Stefan  |m 122405226:Schönland, Stefan  |d 910000  |d 910100  |d 50000  |e 910000PS122405226  |e 910100PS122405226  |e 50000PS122405226  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 6 
999 |a KXP-PPN1938275470  |e 4786581984 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online veröffentlicht: 1. August 2024","Gesehen am 13.10.2025"],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"October 2024"}],"title":[{"title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","title_sort":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis"}],"id":{"eki":["1938275470"],"doi":["10.1001/jamaoncol.2024.2629"]},"name":{"displayForm":["Eli Muchtar, Brendan Wisniowski, Susan Geyer, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Nelson Leung, Angela Dispenzieri, Shaji K. Kumar, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Patricia Ulloa, Vaishali Sanchorawala, Raphael Szalat, Katharine Dooley, Heather Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff, Joan Bladé, M. Teresa Cibeira, Oliver Cohen, Darren Foard, Jullian Gillmore, Helen Lachmann, Ashutosh Wechalekar, Morie A. Gertz"]},"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"recId":"1938275470","relHost":[{"language":["eng"],"part":{"pages":"1362-1369","year":"2024","text":"10(2024), 10 vom: Okt., Seite 1362-1369","issue":"10","volume":"10","extent":"8"},"corporate":[{"display":"American Medical Association","role":"isb"}],"physDesc":[{"extent":"Online-Ressource"}],"recId":"818494301","id":{"issn":["2374-2445"],"zdb":["2810928-4"],"eki":["818494301"]},"title":[{"title":"JAMA oncology","title_sort":"JAMA oncology"}],"note":["Gesehen am 12.10.2017"],"origin":[{"publisherPlace":"Chicago, Ill.","dateIssuedKey":"2015","publisher":"American Medical Association","dateIssuedDisp":"2015-"}],"pubHistory":["1.2015 -"],"disp":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosisJAMA oncology","type":{"media":"Online-Ressource","bibl":"periodical"}}],"person":[{"role":"aut","given":"Eli","family":"Muchtar","display":"Muchtar, Eli"},{"display":"Wisniowski, Brendan","family":"Wisniowski","given":"Brendan","role":"aut"},{"display":"Geyer, Susan","family":"Geyer","given":"Susan","role":"aut"},{"role":"aut","given":"Giovanni","display":"Palladini, Giovanni","family":"Palladini"},{"family":"Milani","display":"Milani, Paolo","role":"aut","given":"Paolo"},{"role":"aut","given":"Giampaolo","display":"Merlini, Giampaolo","family":"Merlini"},{"given":"Stefan","role":"aut","display":"Schönland, Stefan","family":"Schönland"},{"role":"aut","given":"Kaya","display":"Veelken, Kaya","family":"Veelken"},{"given":"Ute","role":"aut","display":"Hegenbart, Ute","family":"Hegenbart"},{"role":"aut","given":"Nelson","family":"Leung","display":"Leung, Nelson"},{"family":"Dispenzieri","display":"Dispenzieri, Angela","given":"Angela","role":"aut"},{"family":"Kumar","display":"Kumar, Shaji K.","given":"Shaji K.","role":"aut"},{"role":"aut","given":"Efstathios","display":"Kastritis, Efstathios","family":"Kastritis"},{"display":"Dimopoulos, Meletios A.","family":"Dimopoulos","given":"Meletios A.","role":"aut"},{"family":"Liedtke","display":"Liedtke, Michaela","role":"aut","given":"Michaela"},{"role":"aut","given":"Patricia","display":"Ulloa, Patricia","family":"Ulloa"},{"role":"aut","given":"Vaishali","family":"Sanchorawala","display":"Sanchorawala, Vaishali"},{"family":"Szalat","display":"Szalat, Raphael","given":"Raphael","role":"aut"},{"family":"Dooley","display":"Dooley, Katharine","given":"Katharine","role":"aut"},{"family":"Landau","display":"Landau, Heather","given":"Heather","role":"aut"},{"display":"Petrlik, Erica","family":"Petrlik","given":"Erica","role":"aut"},{"given":"Suzanne","role":"aut","family":"Lentzsch","display":"Lentzsch, Suzanne"},{"display":"Coltoff, Alexander","family":"Coltoff","role":"aut","given":"Alexander"},{"display":"Bladé, Joan","family":"Bladé","given":"Joan","role":"aut"},{"family":"Cibeira","display":"Cibeira, M. Teresa","given":"M. Teresa","role":"aut"},{"given":"Oliver","role":"aut","family":"Cohen","display":"Cohen, Oliver"},{"given":"Darren","role":"aut","display":"Foard, Darren","family":"Foard"},{"display":"Gillmore, Jullian","family":"Gillmore","given":"Jullian","role":"aut"},{"family":"Lachmann","display":"Lachmann, Helen","role":"aut","given":"Helen"},{"given":"Ashutosh","role":"aut","display":"Wechalekar, Ashutosh","family":"Wechalekar"},{"family":"Gertz","display":"Gertz, Morie A.","given":"Morie A.","role":"aut"}],"language":["eng"]} 
SRT |a MUCHTARELIGRADEDORGA2024